Health officials have given a life-extending drug the green light for widespread NHS, giving hope to thousands of men facing a "death sentence" from prostate cancer.
The National Institute for Health and Care Excellence (Nice) said the drug enzalutamide, also known as xtandi, should be considered for use in the treatment of men with hormone relapsed prostate cancer that has spread to other parts of the body.
Nice said in its draft guidance that it was pleased to recommend the drug, which is manufactured by Astellas Pharma, for patients who have few other treatment options left.
More top news
The NHS could save millions of pounds by allowing more people with a terminal illness to die at home as most wished to do, a charity said.
A self-testing kit for HIV which promises a result in 15 minutes has gone on sale in the UK.
Labour would abolish stamp duty for first time buyers on homes costing up to £300,000, Ed Miliband will announce later.